TICKERNERD
Menu
ZYMEZYMEHealthcare · Biotechnology

ZYME Stock Forecast: Zymeworks, Inc. Price Predictions for 2026-2027

Last close, 8 Sept 2026
$28
−3.70% on the day

The 12 Wall Street analysts covering Zymeworks, Inc. hold a median 12-month price target of $39 — +38.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 78 of 100 as at 8 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$2.1B
Ticker Nerd rank
78 / 100
Median analyst target
$39
Analysts covering
12
Revenue$4.6M−90.6% y/y
Operating income−$42.1M
Net income−$45.0M
Free cash flow−$31.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.4%
1M
+19.4%
YTD
+6.8%
1Y
+85.1%
From 52W high
−9.5%
From 52W low
+85.1%
$15
$31
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ZYME stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Zymeworks, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Sept 2026
78 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
94
Volatility
93
Momentum
89
Revisions
70
Quality
70
Accruals
69
Size
36
Issuance
31
Growth
25

Value (94): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Growth (25): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ZYME stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ZYME, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26ZYMEHigh $60Median $39Low $32

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
12 Buy0 Hold0 Sell
Low $32Median $39High $60

The green dot is the last close — the median target sits +38.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
3 Sept 2026JP MorganMaintainsOverweight$31 → $33
26 Aug 2026CitigroupMaintainsBuy$37 → $38
26 Aug 2026CitigroupMaintainsBuy—
26 Aug 2026CitizensReiteratesMarket Outperform$32
26 Aug 2026CitizensReiteratesMarket Outperform—
26 Aug 2026HC Wainwright & Co.MaintainsBuy$51 → $55
26 Aug 2026HC Wainwright & Co.MaintainsBuy—
10 Aug 2026B. Riley SecuritiesReiteratesBuy$40 → $44
10 Aug 2026B. Riley SecuritiesReiteratesBuy—
7 Aug 2026Truist SecuritiesMaintainsBuy$31 → $32
7 Aug 2026Truist SecuritiesMaintainsBuy—
7 Aug 2026Wells FargoMaintainsOverweight—
7 Aug 2026Wells FargoMaintainsOverweight$37 → $40
5 Aug 2026HC Wainwright & Co.MaintainsBuy—
5 Aug 2026HC Wainwright & Co.MaintainsBuy$46 → $51
7 July 2026Truist SecuritiesMaintainsBuy$28 → $31
7 July 2026Truist SecuritiesMaintainsBuy—
30 June 2026Wells FargoMaintainsOverweight—
30 June 2026Wells FargoMaintainsOverweight$34 → $37
3 June 2026HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ZYME appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ZYME vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Sept 2026, Zymeworks, Inc. returned +85.1% against +19.4% for the S&P 500, dividends included.

ZYME vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180200Oct 25Jan 26Apr 26Jul 26ZYMES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ZYME analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−14.0%
Analysts raising
1
Analysts cutting
0
Fundamentals

Zymeworks, Inc. (ZYME) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.8×

Cheaper than 67% of US stocks

Price / sales
55.1×

Cheaper than 5% of US stocks

Price / book
25.4×

Cheaper than 4% of US stocks

EV / EBITDA
−12.1×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
−90.6%

Higher than 2% of US stocks

Earnings growth (YoY)
−90.6%

Higher than 3% of US stocks

Gross margin
—
Operating margin
−919.0%

Higher than 6% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−72.3%

Higher than 17% of US stocks

Return on assets
−24.1%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Zymeworks, Inc. (ZYME) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Zymeworks, Inc. has a market value of $2.1B and an enterprise value of $1.8B.

  • Revenue in the twelve months to 30 June 2026: $37.1M. The latest quarter shrank 90.6% year on year.

  • Net income over the same four quarters: −$150.0M, a −404.0% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.02.

  • Free cash flow in the twelve months to 30 June 2026: −$120.7M.

  • Zymeworks, Inc. spent $169.8M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 72.0M.

  • Trailing P/E: 3.8×; forward P/E: 24.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Zymeworks, Inc. employs 231 people — $161K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

ZYME vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ZYMEZymeworks, Inc.$2.1B
78
KARDKardigan, Inc.$2.0B
0
GENBGenerate Biomedicines, Inc.$2.0B
1
KLRAKailera Therapeutics, Inc.$2.0B
1
VCELVericel Corp.$2.0B
93
AGIOAgios Pharmaceuticals, Inc.$2.0B
87
COAGHemab Therapeutics Holdings, Inc.$2.1B
1

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Zymeworks, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ZYME news & analysis

Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval

Seeking Alpha · 27 Aug 2026positive

Zymeworks is transitioning from a development-stage biotech into a royalty-driven, revenue-generating platform following the FDA approval of zanidatamab for first-line HER2+ gastroesophageal cancer. The approval expands the eligible patient population and unlocks a $250 million milestone plus tiered royalties, with near-term prospects tied to commercial execution, label expansions, and the pending Theravance acquisition of YUPELRI.

Why it matters — A ZYME watcher would care because the Ziihera approval marks a major strategic shift toward recurring royalty revenue and milestone income, directly shaping the company's valuation and future cash-flow profile.

JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer

Zacks Investment Research · 26 Aug 2026positive

Jazz Pharmaceuticals' Ziihera received FDA approval for expanded first-line use in HER2-positive gastric/gastroesophageal adenocarcinoma (GEA), broadening its addressable market. The drug demonstrated strong progression-free survival and overall survival benefits in the indicated setting.

Why it matters — Ziihera is zanidatamab, a Zymeworks-developed therapy partnered with Jazz, so an expanded FDA approval and broader market could be significant for Zymeworks' commercial outlook.

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks

Zacks Investment Research · 11 Aug 2026positive

Theravance Biopharma reported second-quarter earnings that matched estimates. Following the discontinuation of ampreloxetine, the company implemented cost cuts and is set to be acquired by Zymeworks in a $929 million deal.

Why it matters — A Zymeworks watcher would care because this acquisition expands Zymeworks' scope and represents a significant corporate development for the company.

Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 7 Aug 2026negative

Zymeworks reported a Q2 loss of $0.62 per share, wider than the Zacks Consensus Estimate of a $0.56 loss and versus earnings of $0.03 per share in the same quarter a year ago, while revenue beat estimates.

Why it matters — The results show a year-over-year swing from profit to a loss that was larger than analysts expected, which is directly relevant to ZYME watchers tracking quarterly performance.

Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 6 Aug 2026positive

Zymeworks reported its second quarter 2026 financial results and corporate update, highlighting a U.S. PDUFA target action date for zanidatamab that could trigger a $250 million U.S. approval milestone and up to $190 million in additional global regulatory milestones. The company also expects its acquisition of Theravance Biopharma to close in the second half of 2026, advanced its R&D pipeline, repurchased $49.4 million of common shares, and held $322.5 million in cash and securities as of June 30, 2026.

Why it matters — The update signals key near-term catalysts—zanidatamab's U.S. approval milestone and the Theravance acquisition adding commercial cash flows—alongside a strong cash position and an active share repurchase program.

FAQ

Frequently asked questions about ZYME stock

What is the ZYME stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Zymeworks, Inc. have a median 12-month price target of $39, with estimates ranging from $32 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ZYME stock a buy right now?

Of the 12 analysts covering Zymeworks, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zymeworks, Inc. 78 out of 100 across roughly 4,600 US stocks as at 8 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ZYME?

As at 8 Sept 2026, Zymeworks, Inc. ranks 78 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (94 of 100).

Will ZYME stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +38.7% from the last close, and Ticker Nerd's factor model ranks Zymeworks, Inc. 78 out of 100 as at 8 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ZYME stock forecast for 2030?

No analyst covering Zymeworks, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZYME are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $32 to $60 over the next 12 months.

How has ZYME stock performed over the past year?

Zymeworks, Inc. returned +85.1% over the 12 months to 8 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Zymeworks, Inc. do?

Zymeworks Inc. is a biotechnology company focused on discovering, developing, and commercializing multifunctional biotherapeutics for difficult-to-treat diseases.

What is the latest news on ZYME?

The most recent item we track (Seeking Alpha, 27 Aug 2026): "Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval". Zymeworks is transitioning from a development-stage biotech into a royalty-driven, revenue-generating platform following the FDA approval of zanidatamab for first-line HER2+ gastroesophageal cancer. The approval expands the eligible patient population and unlocks a $250 million milestone plus tiered royalties, with near-term prospects tied to commercial execution, label expansions, and the pending Theravance acquisition of YUPELRI.

Company

About Zymeworks, Inc.

Zymeworks Inc. is a biotechnology company focused on discovering, developing, and commercializing multifunctional biotherapeutics for difficult-to-treat diseases. Its current work centers on oncology and other serious conditions, including inflammation and autoimmune disorders, using advanced antibody-based platforms designed to create highly differentiated drug candidates. The company’s portfolio includes licensed healthcare assets as well as clinical and preclinical programs, with products and candidates such as Ziihera and pasritamig among its notable programs. Zymeworks also develops antibody-drug conjugates and multispecific therapeutics, reflecting a broader strategy of combining proprietary platforms with partnered assets to address unmet medical needs. The company plays a specialized role in the biopharmaceutical market by advancing targeted therapies that aim to improve treatment options across cancer and immunology-focused segments.

CEO Mr. Kenneth H. Galbraith C.A. · 231 employees · United States · https://www.zymeworks.com